|
|
|
| home > ebr > Winter 2005 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR. |
 |
| |
|
|
| In her Editor’s Letter, Dr Helen Tayton-Martin looks at the technologies, trends and challenges presented in this issue of EBR |
|
|
|
|
| Will the US still be the base of power for biotechnology a decade from now? G Steven Burrill at Burrill & Company considers the regions that stand to profit from the globalisation of biotech and become contenders for Western dominance, in New Windows in the Corridors of Power |
|
|
| Can shrewd decision-making and business acumen reduce uncertainty in a game of chance? Richard Philpott at Progenta examines the importance of finely-tuned management skills, in Improving the Odds at the Biotech Casino |
|
|
| In Indian Biotech – A Fledgling Industry Takes Flight, Dr Amal K Mukhopadhyay and Erich U Mayer at van Rooijen & Partners Ltd consider the country’s strengths in science, IT and manpower, and the opportunities for collaboration that they present |
|
|
| Biotech SMEs have high requirements in terms of capital, business environment, people, and public and political support. Laurens Theunis at Europabio recommends the exploration of new policies that engage with these needs and promote the full realisation of Europe’s potential in the life sciences arena, in European Biotech: From Capital to Critical Mass |
|
|
| Innovative Financing – Are German Service Companies Rising to the Challenge? Alexander Knoll at BioGenes GmbH investigates the improvements needed, particularly in financing options, to maintain their track record of success |
|
|
|
|
| Nicole Yost at BTG and Mark Clements, freelance Editor and writer, examine the promises offered by targeted cancer therapeutics – one of the richest areas of current medical research – in In Search of the Perfect Match |
|
|
| From the West Nile Virus to avian flu and the threat of bioterrorism, Battling Biological Threats is a priority for the UK Government, as discussed by Howard S Tranter,Mitch V Rogers and Jackie Duggan at the Health Protection Agency |
|
|
| Immunotherapy, monoclonal T cell receptors and vaccines present alternatives to current antitumour approaches that avoid many of the pitfalls of traditional treatments.Neil MacKenzie and Dr Helen Tayton-Martin at Avidex review developments in an area of great unmet medical need, in Targeting Tumours for Attack |
|
|
| In our third article on cancer therapeutics, Signals of Success, John L Lewis and Norman J Maitland at the University of York examine the role of pathways – in particular Hedgehog and Wnt – as regulators of the activity of stem cells in prostate cancer, and their potential to be novel treatment targets |
|
|
|
|
| In Mapping the Interactome, Derek J Quinn and Christopher J Scott at Queen’s University, Belfast, and Richard J Buick at Fusion Antibodies, look at the accrual of information on protein-protein interactions – a process that may expand drug discovery strategies and lead to new therapies |
|
|
Advances in assays, microarrays and genomics are bringing us nearer to a future where pharmacogenetic tests match patients with DNA-specific therapies. This would dramatically alter the way in which disease is diagnosed, monitored and treated. Ram Vairavan and Dr Phillip Kim at Autogenomics, Inc, provide an overview, in Tailor Made – The End of One Size Fits All?
|
|
|
Dr Wolfgang Pusch and Dr Markus Kostrzewa at Bruker Daltonics pose the benefits of MALDI TOF MS across a range of disciplines, in A Paradigm Shift in Proteomics. From biomarker discovery, to diagnosis and monitoring of drug efficacy, new applications are emerging that will further enrich the protein biochemistry revolution initiated by mass spectrometry
|
|
|
In Speed is of the Essence, Christine Miller at Agilent Technologies and Mark Stahl at Roche Diagnostics GmbH explore the merits of high-throughput LC/MS in reducing analysis time, increasing productivity and, ultimately, furthering our knowledge of peptides and proteins. This method, they assert, may solve many of the limitations of current technologies
|
|
|
|
|
Diverse in function and low in toxicity, peptides offer a wealth of unclaimed intellectual property. In Therapeutic Peptides under the Spotlight, Catherine Pichereau and Claude Allary at Bionest discuss a field attracting a surge of interest, as years of fundamental research comes to fruition
|
|
|
Almost 170 protein-based drugs have gained approval in Western markets, and twice that number are in clinical trials.However, while this is a realm of great potential, much work remains to be done in order to continue its growth. Professor Gregory Gregoriadis at Lipoxen unravels possibilities and problems in peptide and protein therapeutics, in Polysialylation: The New Way
|
|
|
Jim Hampton at American Peptide Company looks at Peptides and Proteins – The Case for Conjugation, offering solutions to the high cost of administration through chemical modification with PEG.This process can improve in vivo bioavailability, which is frequently limited due to a number of endogenous factors
|
|
|
|
|
Grand Designs must be rigorously planned and ‘future proof’. Roger Freestone at Delta presents a guide to constructing a biomanufacturing facility, from initial concept through to completion of the project on schedule and within budget
|
|
|
Should manufacturing be considered a cumbersome and inevitable drain on expenses,or an opportunity to integrate additional value with long-term rewards? Joanne McCudden and Andrew Lewin at SynCo Bio Partners BV present the case for a fresh approach, in Manufacturing Success
|
|
|
Mark P Lewis at UCL Eastman Dental Institute and Robert Sexauer at Isolagen UK review the origins of tissue engineering, and examine current manufacturing challenges and nascent solutions, in The Art of Reconstruction
|
|
|
|
|
In Translating Technology into Industry, Dr Mark Tock at The Sheffield Bioincubator considers the strategies promoting growth in and around the former Steel City, such as the White Rose Consortium, which links Leeds, Sheffield and York universities, and facilitates communication between entrepreneurs and academia
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Discussing developments on Highly Potent APIs with industry expert, Richard Arnett for the HPAPI USA conference 2019
Ahead of the 2019 HPAPI USA Conference taking place in Boston on 21st – 22nd October, SMi caught up with Richard Arnett, Manager, Industrial Hygiene, Pharmascience who is speaking on Day Two of the agenda. Richard shared his thoughts on how the industry has developed and briefly touched on what he will be discussing in October.
More info >> |
|
 |
White Papers |
 |
|
Biosimilars In Emerging Markets: Is It A Level Playing Field?
PRA Health Sciences (PRA)
Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >> |
|
 |
Industry Events |
 |
World Vaccine Congress Washington
7-9 April 2020, Walter E Washington Convention Center, Washington, US
The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >> |
|
|
